natgillin/translations-raw huggingface dataset:
Further studies have shown that treatment with adenosine or 2-chloroadenosine increased immobility time in the mouse forced swimming test, another animal model of depression generally considered reliable (Porsolt et al., 1977, Arch Int Pharmacodyn Ther 229: 327-336). 
Daljnja ispitivanja pokazuju da tretman s adenozinom ili 2-kloroadenozinom povećava vrijeme imobilizacije kod miševa, primjenom prislinog test plivanja, drugi životinjski modeli depresije općenito se smatraju pouzdanima (Porsolt et al., 1977, Arch Int Pharmacodyn Ther 229:
RX is substituted or unsubstituted C1-4alkylene wherein up to 2 carbon atoms can be optionally replaced with CO, NSO2R1, NRY, CONRY, SO, SO2 or O; 
RX je supstituiran ili nesupstituiran C1-4alkilen u kome do 2 atoma ugljika mogu biti po izboru zamijenjena sa CO, NS2R, NRY, CONRY, SOL, SO2 ili O;
The method according to claim 1, wherein the drying oven is kept under vacuum and wherein the steps of entering the pouch into and removing the pouch from the drying oven is performed through respective air-locks. 
Postupak prema zahtjevu 3, naznačen time da se u peći za sušenje održava vakuum i pri čemu se koraci ulaska vrećicu u i uklanjanja vrećice iz peći za sušenje provode kroz odgovarajuće zračne komore.
wherein a first plurality of the data objects is associated with a base realm representing data shared across all users of the database; wherein a second plurality of the data objects is associated with a first child realm, wherein the first child realm represents data local to a project, wherein a first user is associated with the first child realm, the second plurality of data objects being only visible to users associated with the first child realm; 
gdje je svaka verzija jednog ili više podatkovnih objekata povezana bilo s potpodručjem jednog ili više potpodručja ili s područjem baze; gdje je prva skupina verzija jednog ili više podatkovnih objekata spremljena u verzionirajućoj bazi podataka povezana s područjem baze u kojem su korisnici baze podataka objavili podatke, gdje je prva skupina verzija jednog ili više podatkovnih objekata povezana s područjem baze vidljiva korisnicima baze podataka;
In this embodiment, the advantage of the process, namely to reproducibly generate aggregated conformation prion protein at high yield, due to the precise control of the shear force intensity applied, is used to determine that the original sample contained aggregated conformation prion protein when an increase of the aggregated conformation prion protein is detected. 
Postupak prema zahtjevu 8, naznačeno time da je spoj dodan prvom alikvotu tekućeg sastava, drugi alikvot ostaje bez dodanog spoja, te se daljnjom primjenom sile smicanja zamijećuje promjena u prvom alikvotu u odnosu na prionski protein agregirane konformacije u drugom alikvotu.
The process according to claim 1, wherein the final solids content of the aqueous suspension obtained in step d) is at least 1 wt % higher than the initial solids content of the aqueous suspension obtained in step b). 
Uporaba vodene suspenzije sa visokim udjelom krutih mineralnih materijala dobivenih postupkom prema bilo kojem od zahtjeva 1 do 18 u papiru, bojama za prevlačenje papira, bojama i plastici, naznačena time da je konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) od 83 do 85 % tež..
Rf is chosen from the group consisting of hydrogen, hydroxyl group, halogen or forms (C=O) a carbonyl group with the carbon atom to which it is linked; 
R' se bira iz skupine koju čine vodik, hidroksilna skupina, halogen, ili tvori karbonilnu skupinu s atomom ugljika na kojeg je vezan;
the method comprising: 
metoda uključuje:
● Monoclonal Antibodies. 
Monoklonalna protutijela.
15-50 wt.% of a palm oil fraction having a melting point within the range of 27-38 °C; and wherein said fat blend is further characterised by a solid fat content at 25 °C of less than 10 wt.%. 
- 15-50 %, težinski, frakcije palminog ulja s rasponom tališta od 27-38 "€; gdje navedena smjesa masti je dodatno naznačena time što sadržaj čvrste masti na 25 € je manji od 10 %, težinski.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The method of claim 1 further comprising a preparation of the compound of formula (7), wherein the method comprises treating a compound of formula (6): 
Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6):
The method of claim 4, wherein said produce comprises bananas. The method of claim 5, wherein the ratio of the banana-specific perforation of the bottom enclosure of said bag to the banana-specific perforation of the top enclosure of said bag is from 0.3:1 to 5:1. 
Postupak iz patentnog zahtjeva 5, pri čemu odnos perforacije specifične za bananu zatvaranja donje strane spomenute vrećice na perforaciji specifičnoj za bananu gornjeg zatvaranja spomenute vrećice je od 0,3:1 do 5:1.
a light chain variable domain (VL) of sequence SEQ ID No. 
varijabilnu domenu lakog lanca (VL) sekvencije SEQ ID br.
In an alternate embodiment, the kit comprises (1) a first pharmaceutical composition comprising dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof, (2) a second pharmaceutical composition comprising any one the antibodies described herein or combination thereof, (3) instructions for separate administration of said first and second pharmaceutical compositions to a patient, wherein said first and second pharmaceutical compositions are contained in separate containers and said second pharmaceutical composition is administered to a patient requiring neutralization or partial neutralization of dabigatran or 1-O-acylglucuronide of dabigatran. 
(a) prvi farmaceutski sastav koji obuhvaća dabigatran, dabigatran-eteksilat, predlijek od dabigatrana ili njegovu farmaceutski prihvatljivu sol; (b) drugi farmaceutski sastav koji obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 7; (c) upute za odvojenu primjenu prvog i drugog farmaceutskog sastava kod pacijenta; pri čemu se navedeni prvi i drugi farmaceutski sastav nalaze u odvojenim spremnicima, dok se drugi farmaceutski sastav upotrebljava za primjenu kod pacijenta kojemu je potrebna neutralizacija ili djelomična neutralizacija dabigatrana ili 1-O-acilglukuronida od dabigatrana.
Process according to any one of the preceding claims, characterized in that a stream enriched with 5-hydroxymethyl-2-furfural from previous dehydration reactions, in particular dehydrations of sugars, is employed as a starting material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se kao polazni materijal koristi tok obogaćen s 5-hidroksimetil-2-furfuralom iz prethodnih reakcija dehidracije, naročito dehidracije šećera.
The implantable prosthetic device of claim 9, wherein the first and second leaflet receiving surfaces are scalloped shaped. 
Protetski uređaj koji se može implantirati prema patentnom zahtjevu 8, naznačen time što su površine koje prihvaćaju prvo i drugo jedro školjkasto oblikovane.
The compound according to claim 1 where R1 is methyl, ethyl, or phenyl optionally substituted with 1 to 2 fluoro groups. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je metil, etil ili fenil, izborno supstituiran s 1 do 2 fluorne skupine.
The method as claimed in claimed 1, wherein, a procedure of corrosion resistance (36) is subsequently proceeded after said procedure of thread formation (34) in order to coat with a rust-resistant layer (46) on an outer surface of said integral fastener (4) for corrosion protection. 
Postupak prema zahtjevu 1, naznačen time što postupak dodavanja otpornosti na koroziju (36) slijedi nakon spomenutog postupka oblikovanja navoja (34), pri čemu se dodaje sloj otporan na koroziju (46) na vanjsku površinu cjelovitog vijka (4) radi zaštite od korozije. t>&
Lesinurad or a pharmaceutically acceptable salt thereof and allopurinol for use as claimed in any of claims 2 to 7 for administration together with food. 
Lesinurad ili farmaceutski prihvatljiva sol i alopurinol za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 7 za primjenu zajedno s hranom.
The polymeric device material of claim 10 wherein the amount of hydrophilic side-chain macromer is 1 to 5% (w/w). 
Polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 9, naznačen time što količina hidrofilnog pobočnog makromera je 1 do 5 % (težinski).
These and other objects according to this invention are achieved by a recoil damper system according to that set out in claim 1. 
Ovi i drugi ciljevi koji su u skladu s ovim izumom postižu se pomoću sustava za prigušivanje trzanja oružja, koji ciljevi su u skladu s onim sustavom koji je naveden u patentnom zahtjevu 1.
The method of any of Claims 1 to 5, wherein the aqueous acetate or glutamate buffered G-CSF composition provided in step (a) has a volume of from 0.1 ml to 8 l, preferably of from 5 ml to 4 l, and more preferably of from 100 ml to 1.5 l. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time, da vodeni acetat ili glutamat puferiranog G-CSF-sastava, koji je pribavljen u koraku (a), ima volumen od 100 ml do 4 l, i još bolje od 100 ml do 1,5 l.
The lipid compound according to claim 5, wherein X is a carboxylic acid. 
Lipidni spoj prema zahtjevu 11, pri čemu X je karboksilna kiselina.
Method according to claim 1, characterised in that the flue gases (A) are denitrified to at least 60%. 
Postupak prema jednom zahtjevu od 1 do 4, naznačen time da su dimni plinovi (A) denitrificirani do barem 60%.
The supporting structure of antennas 42, 43 is also inserted inside cavity 72 . 
Oslonačka konstrukcija antena 42, 44 se također umeće unutar šupljine 72.
The process of claim 1 wherein R and R' together with the nitrogen atom they are linked to form a phthalimido group. 
u kojem R i R’ zajedno s dušikovim atomom za koji su vezani predstavljaju zaštićenu amino-skupinu, sa spojem formule (XVI):
a Gly, Leu, Met or Trp at position 407 and a Lys at position 409, and wherein the first CH3 further has a Tyr at position 407; or 
(iii) Gly, Leu, Metili Trp na poziciji 407 i Lys na poziciji 409, te pritom prvi CH3 ima Tyr na poziciji 407; ili
The method of claim 14, wherein the second dose of fentanyl, or a pharmaceutically acceptable salt thereof, is administered to the subject no earlier than 5 minutes after the time the first dose of fentanyl, or a pharmaceutically acceptable salt thereof, is administered to the subject. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 7, naznačen time što se dopunska doza fentanila ne daje ranije od 5 minuta nakon prethodne doze fentanila.
Rail vehicle according to claim 14, characterised in that the upper damping arrangement (100) comprises a damper (101) which extends diagonally relative to the longitudinal direction of the vehicle. 
Å insko vozilo prema zahtjevu 13, naznačeno time što gornji prigušni sklop (100) obuhvaća prigušivač (101) koji se pruža dijagonalno u odnosu na uzdužni smjer vozila.
said light chain variable region comprises a CDR1 having a sequence as set forth in SEQ ID NO.20, a CDR2 having a sequence as set forth in SEQ ID NO.21, and a CDR3 having a sequence as set forth in SEQ ID NO.38; or 
i navedena varijabilna regija lakog lanca sadrži CDR1 koji ima sekvencu kako je navedeno u SEQ ID NO.20, CDR2 ima sekvencu kako je navedeno u SEQ ID NO.21, i CDR3 koji ima sekvencu kako je navedeno u SEQ ID NO. 38;
A compound according to claim 3, having the structure wherein m is not 0, preferably where Z is CO2Q, Q is hydrogen, and m is 1, 2, or 3. 
CO gdje m nije 0. Tvar u skladu s patentnim zahtjevom 7, pri čemu je Z jednak CO2Q, Q je vodik, a mje 1, 2, ili 3.
The mixture was extracted with 2×300 mL portions of chloroform. 
Smjesu se ekstrahira s 2 obroka po 300 mL kloroforma.
A stack of mutually connected devices of claim 2, wherein the stack includes connecting structure configured to connect a top or bottom of the stack to the top or bottom of an adjacent, like stack in an end-on fashion. 
Skup međusobno povezanih uređaja iz zahtjeva 2, pri čemu skup uključuje priključnu strukturu koja je postavljena kako bi povezivala vrh ili dno skupa s vrhom ili dnom susjednog skupa.
The dried pellets were sieved through a 500 um sieve. 
Osušene pelete se prosiju kroz 500 um sito.
The method of any one of claims 1 to 8, wherein the buffer solution further comprises a pyrophosphate salt. The method of any one of claims 1 to 8, wherein the monomeric platinum pyrophosphate complex comprises two amine ligands independently selected from NH 3, substituted or unsubstituted aliphatic amines, and substituted or unsubstituted aromatic amines. 
Postupak prema bilo kojem od zahtjeva 1 do 19, naznačen time da navedeni spoj platina dihalogenid ima formulu: [image] pri čemu su R1 i R2 dva liganda amina koji su neovisno odabrani od NH3, supstituiranih ili nesupstituiranih alifatskih amina, i supstituiranih ili nesupstituiranih aromatskih amina; i X je halogen odabran od Cl, Br, i I.
According to the teaching, an antibody is specific for CLDN6 if it is capable of binding to CLDN6 but is not capable of binding to other targets, in particular claudin proteins other than CLDN6 such as CLDN9, CLDN4, CLDN3 and CLDN1. 
Antitijelo suglasno zahtjevima 1 ili 2, naznačeno time da nije u biti sposobno da se veže za CLDN4, koji je asociran na membrani stanice koja eksprimira CLDN4 i/ili nije u biti sposobno da se veže za CLDN3 asociranim za membranu stanice koja eksprimira CLDN3.
R10, R11 represent, independently from each other, a group selected from hydrogen, C1-C2-alkyl-; 
R', R' predstavljaju, međusobno neovisno, skupinu koja je odabrana od vodikovog atoma, fluorovog atoma ili klorovog atoma;
Statement 100. The method of statement 99, wherein the pulmonary disease or disorder is selected from at least one of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary vasoconstriction, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.
In the commercializing steps, storage in tightly closed containers, protected from air and from sunlight, and under inert gas is also adopted. 
U koracima komercijalizacije, također se prihvaća pohranjivanje u hermetički zatvorenim spremnicima, zaštićenim od zraka i svjetlosti, i pod inertnim plinom.
a supercritical trough including a trough body, a material supply device, and a supercritical fluid supply device; wherein said material supply device supplies a material to said trough body, and said supercritical fluid supply device supplies a supercritical fluid to said trough body, while said trough body holds the material and the supercritical fluid that have been supplied thereto, and allows the material and the supercritical fluid to form an evenly-distributed solution; and a catalyst trough including a trough body and a product drain device; wherein said trough body holds a catalyst therein, and said product drain device is for draining a product away from said trough body of said catalyst through; said catalyst trough and said supercritical trough are connected so as to allow said evenly-distributed solution to come into contact with said catalyst and undergo catalytic reactions. 
Uređaj za superkritično dozrijevanje, naznačen time što se sastoji od: superkritičnog korita, uključujući trup korita, uređaj za dobavu materijala i uređaj za dobavu superkritičnog fluida, gdje navedeni uređaj za dobavu materijala dobavlja materijal u navedeni trup korita, gdje navedeni uređaj za dobavu superkritičnog fluida dobavlja superkritični fluid u navedeni trup korita, dok navedeni trup korita sadrži materijal i superkritični fluid kojima je napunjen, što omogućuje da materijal i superkritični fluid tvore homogenu otopinu; i katalizatorskog korita, uključujući trup korita i uređaj za uzimanje proizvoda; gdje navedeni trup korita sadrži katalizator, a navedeni uređaj za uzimanje proizvoda služi za utimanje proizvoda iz navedenog trupa korita navedenog katalizatorskog korita; navedeno katalizatorsko korito i navedeno superkritično korito su povezana, tako da se omogući da navedena homogena otopina dođe u kontakt s navedenim katalizatorom, te da dođe do katalitičkih reakcija.
calculating, with a computer system, a first value of a first parameter based on the amounts of DNA fragments at multiple sizes, the first parameter providing a statistical measure of a size profile of DNA fragments in the biological sample; 
izračunavanja prve vrijednosti prvog parametra na osnovu količina fragmenata DNK pri različitim veličinama pri čemu prvi parametar pruža statističku mjeru profila veličine fragmenata DNK u uzorku plazme;
A composition according to any one of claims 1-7, wherein the second propellant is a C3-5alkane selected from the group consisting of n-propane, isopropane, n-butane or isobutane. 
Kompozicija prema bilo kojem od zahtjeva 1-13, pri čemu je drugo pogonsko sredstvo smjese pogonskih sredstava C3-5alkan, a prvenstveno je izabran iz grupe koja se sastoji od n-propana, izopropana, n-butana i izobutana.
The binder according to claim 3, wherein the latent hydraulic materials and/or pozzolans are selected from the group consisting of brick dust, fly ashes, tuff, trass, sediments having soluble silica, annealed clays and shale, pozzolanic synthetic glasses, ground granulated blast furnace slag, latent hydraulic synthetic glasses, calcium fly ashes, and combinations thereof. 
0 do 30% po težini Vezivno sredstvo sukladno zahtjevu 3, naznačeno time što su latentni hidraulički materijali iili puzolani odabrani između ciglene prašine, pepela, sedre, trasa, taloga s visokim udjelom topivog silicija,klajene gline i škriljevca, puzolanskih sintetičkih stakala, troske, latentnih hidrauličkih sintetičkih stakala, pepela bogatog vapnom i njihovih kombinacija.
In another embodiment described, said first solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, Dimethylsulfoxide, diphenyl ether, Dimethylacetamide, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno prvo otapalo se bira iz skupine koju čine ksilen, V-metilpirolidinon, dimetil-sulfoksid, difenil-eter, dimetilacetamid, te smjese 2 ili više njih.
sterilizing the noradrenaline solution. 
sterilizacija otopine noradrenalina.
Then, the column was flushed with 10 BV of wash buffer PBS 1X pH 6.1 ± 0.1, conductivity 16 ± 2 mS/cm. 
Tada, kolona je bila oprana s 10 BV pufera za ispiranje PBS IX pH 6.1 + 0.1, provodljivost 16 + 2 mS/em.
A container (1) according to claim 6 or 7, characterised in that the pressure medium source is a capsule (24) of the pressure medium under pressure, whereby the pressure medium is a gas. 
Spremnik (1) u skladu s patentnim zahtjevom 6 ili 7, naznačen time što je izvor tlačnog medija kapsula (24) za tlačni medij pod tlakom, gdje je tlačmi medij plin.
The organic layer was washed with brine, dried over Na2SO4, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes/triethylamine 500/500/6 to 800/200/7 to afford compound 5c (7.26 g, 70%) as a white foam. 
Organski sloj ispere se slanom vodom, osuši preko Na,SO,, koncentrira, te pročisti kromatografijom na stupcu silikagela, uz eluiranje smjesom etil-acetat/heksani/trietilamin 500:500:6 do 800:200:7 kako bi se dobilo spoj Se (7,26 g, 70 %) u obliku bijele pjene.
Rifle comprising a recoil damper system according to claim 1 . 
Puška koja ima sustav za prigušivanje trzanja koji je u skladu s patentnim zahtjevom 1.
The nucleic acid molecule according to claim 6, comprising a nucleotide sequence depicted in SEQ ID NO 89, or its conservative sequence variant. 
Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida prikazanu u SEQ ID NO 89 i njenu konzervativnu varijantu sekvence.
The compound of claim 1, characterized by the structure of formula VIII: 
VII 4. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VIII:
A fire-extinguisher according to Claim 2, characterized in that the activation element (14) is associated with the fire-extinguisher in a manner such that, in an inactive condition, the activation element (14) is held remote from the inflammable charge (13) and, in an active condition, can be brought into contact with a surface (13a) of the inflammable charge in order to ignite it by friction. 
Aparat za gašenje vatre prema zahtjevu 1, naznačen time, da je sredstvo za ručno držanje (15) odvojivo ugrađeno na aparatu za gašenje vatre. Aparat za gašenje vatre prema zahtjevu 1 ili 2, naznačen time, da je pogonski element (14) oblikovan kao utikač koji se može umetnuti u šupljinu ručke (2) kako bi se površina (14a) pridržavala u zaštićenom položaju od vanjskog prostora, kada je ona u stanju mirovanja.
The control unit of claim 19, wherein said second or said third interface can be manipulated by a user when said minimally invasive surgical tool is frozen in position. 
Kontrolna jedinica iz zahtjeva 10, naznačena time da navedeno sučelje za dlan (40) 1 navedeno sučelje upravljano dodirom prsta (60) mogu biti manipulirani od strane korisnika kad je naveden minimalno invazivan kirurški alat (12) zaustavljen u unaprijed postavljenoj poziciji.
The animal of Clause 1, further comprising at an endogenous non-human B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide, wherein the animal expresses the human or humanized B2 microglobulin polypeptide. 
Životinja prema zahtjevu 1, naznačena time, da nadalje na endogenom ne-humanom B2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid, pri čemu životinja izražava humani ili humanizirani B2-mikroglobulin-polipeptid.
A stable formulation suitable for subcutaneous administration comprising at least 100mg/ml CTLA4Ig molecule, a sugar selected from the group consisting of sucrose, lactose, maltose, mannitol and trehalose and mixtures thereof and a pharmaceutically acceptable aqueous carrier, wherein the formulation has a pH range of from 6 to 8 and a viscosity of from 9 to 20 cps, and the weight ratio of sugar:protein is 1.1:1 or higher. 
E Formulacija pogodna za subkutanu primjenu koja sadrži 125mg/ml CTLA4Ig molekule, šećer izabran iz grupe koju čine saharoza, laktoza, maltoza, manitol 1 trehaloza i njihove smjese, i farmaceutski prihvatljiv vodeni nosač, pri čemu formulacija ima pH opseg od 6 do 8 i viskozitet od 9 do 20 mPa:s, i težinski odnos šećera:proteina je 1.1:1 ili viši.
The method of claim 1, wherein the monoclonal antibody or the antigen binding portion thereof is administered in combination with a therapeutically effective amount of a second agent, which is an anti-cancer agent other than the monoclonal antibody or the antigen binding portion thereof. 
(b) antitijelo ili njegov dio koji se vezuje za antigen je primjenjeno u kombinaciji s drugim terapijskim sredstvom, pri čemu je drugo terapijsko sredstvo drugo antitijelo ili njegov dio koji se vezuje za antigen ili drugo sredstvo protiv karcinoma.